Perimeter Medical Imaging AI (PINK) investor relations material

Market opportunity and financial highlights

• U.S. serviceable available market for breast cancer surgery estimated at $650M, with global TAM at $17B across all cancer, biopsy, surgery, and pathology applications.

• Multi-year growth runway with high-margin, recurring consumable, software, and service revenue streams.

• Revenue up 157% YoY in Q3-2025, with first nine months of 2025 revenue 88% higher than all of 2024.

• Attractive financial model driven by procedure-based consumable usage and expanding installed base.

• Low breakeven threshold and increasing operating leverage as utilization grows.

Technology and clinical impact

• Patented S-Series OCT has 510(k) clearance; next-gen Claire OCT with AI received FDA PMA approval in March 2026.

• Claire OCT system with ImgAssist AI demonstrated statistically significant reduction in residual cancer during surgery (p = 0.0050).

• Technology provides ultra-high-resolution, real-time imaging, 10x sharper than ultrasound and 100x more detailed than MRI.

• Wide-field OCT enables margin assessment in the OR within minutes, correlating strongly with post-op pathology.

• AI algorithms highlight suspicious areas, improving efficiency and accuracy of margin assessment.

Strategic growth and commercialization

• 22 systems deployed commercially by end of 2025, with expansion focused on U.S. breast surgery market and adjacent indications.

• Commercialization strategy targets hospital networks, academic centers, and high-volume surgeons for adoption.

• Expansion plans include international markets and distribution partnerships.

• Recurring revenue mix grows with installed base; strategic partnerships and platform extensions under evaluation.

• Management and ownership structure aligned with long-term shareholder value creation.